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Practice management and decision making 
Introduction 
Achieving responsible and sustainable medicines use in farm animal practice is a significant and timely 
challenge that veterinary and human health professionals must tackle together (Department of Health, 2013, 
O'Neill, 2015).  Though responsible antimicrobial (AM) use should be of primary importance, to focus on it 
alone is too narrow an approach, and risks missing the benefits of achieving a more holistic understanding 
of medicines use on farm in achieving improved animal health and welfare. For example, non-steroidal anti-
inflammatory drug (NSAID) use can provide valuable insight into animal welfare and pain management, while 
the level of implementation of vaccination protocols can establish whether attitudes are geared towards 
preventive or reactive approaches. 
The starting point must be to understand current patterns of prescribing by veterinary surgeons (VS) 
(Newman and others 2011, Gibbons and others 2013) and actual use on farms, which may not be the same 
as the intended use.  Though progress has been made, the twin challenges of confronting partial compliance 
with treatment protocols (Sawant and others 2005) and capturing accurate farm-level data on medicines 
use remain (Department of Health 2014). 
Sawant and others (2005) found that on 93% of 113 dairy farms surveyed in Pennsylvania, antibiotics were 
administered by farm staff rather than the VS and only 32% of producers sought veterinary advice before 
administration. In the same study only 24% of producers said that they always completed a course of 
antibiotic (Sawant and others, 2005).  However, this is something that industry is taking seriously.  In a more 
recent UK survey of dairy farmers (Jones and others 2015), 100% of respondents had either reduced or 
planned to reduce antibiotic use. Seventy percent thought that reducing antibiotic usage was a good thing 
to do with VS being the most influential source of information.  Farmers that received a greater proportion 
of their income from milk production or were more likely to remain in milk production were more likely to 
demonstrate a positive intention to reduce antibiotic use (Jones and others 2015). This demonstrates that 
there is clear recognition amongst dairy farmers that this is an important aspect of herd health management 
(HHM) and VS are well-placed to drive change in this area.  
Although prescription only medicines (POM-V) are often administered to farm animals by farm staff, the line 
of responsibility for their use is clear: it is the VS who must prescribe, only after performing a clinical 
assessment of an animal or group of animals and establishing a diagnosis, and ensure that the medicines are 
used correctly. Clear guidelines have been produced (British Veterinary Association 2009, Royal College of 
Veterinary Surgeons 2012). This responsibility is currently shared between practitioners working for a 
diverse range of privately owned and often competing veterinary businesses.  
At the coal face, establishing responsible medicines use is an essential part of HHM, practice clinical 
governance and the practise of evidence-based veterinary medicine (EBVM) (Figure 1). 
 
Figure 1. Establishing responsible medicines use 
 
• Improved HHM – Improving farm animal health and welfare by cultivating better farm 
management practices. These measures help to reduce disease alongside developing evidence-
based and responsible standard treatment protocols, and should mean that fewer treatments are 
required and when used they are applied appropriately. This is particularly important in farm animal 
practice because the majority of treatments are AMs and so improved HHM should ultimately 
reduce AM use and with it the drive towards AMR development. This should be a continuous and 
adaptive process (Figure 2), built upon an ongoing and collaborative dialogue between the VS and 
farmer, both of whom can bring their expertise together to improve HHM. 
 
Figure 2. Cycle of HHM and clinical governance 
 
• Practice clinical governance – Given that AM prescribing constitutes a significant proportion of 
veterinary treatments, their use and AMR must be considered as part of clinical governance.  
Monitoring treatment outcomes - both successes and failures - and reviewing protocols accordingly 
are essential pillars of responsible veterinary practice and part of applying EBVM. The starting point 
should be to establish baseline patterns of medicines usage at practice-level alongside simple 
measures of treatment outcome for common and important conditions. Again this should form part 
of a continuous cycle of improvement (Figure 2).  
 
• Evidence-based veterinary medicine (EBVM) – An evidence-based approach will help to ensure that 
medicines are only prescribed when they are indicated, and that the most-appropriate treatment is 
selected. 
The World Health Organisation (WHO) has categorised AMs with respect to their importance in terms of 
human health (WHO, 2012).  The two criteria used to group AMs are described in Table 1. 
Table 1. – WHO categorisation of AMs with respect to their importance for human health 
Category Description 
Criterion 1 An antimicrobial agent which is the sole, or one of limited available therapy, to treat serious 
human disease. 
Criterion 2 Antimicrobial agent is used to treat diseases caused by either: (1) organisms that may be 
transmitted to humans from non-human sources or, (2) human diseases causes by 
organisms that may acquire resistance genes from nonhuman sources. 
Critically important Those antimicrobials which meet both Criterion 1 and Criterion 2 are termed: critically 
important for human medicine.  
Highly important Those antimicrobials which meet either Criterion 1 or Criterion 2 are termed: highly 
important for human medicine. 
Important Those antimicrobials which meet neither Criterion 1 nor Criterion 2 are termed: important 
for human medicine. 
 
Current farm animal veterinary examples of critically important AMs are highlighted in Table 2. Within this 
group, there is particular concern over the use of third and fourth generation cephalosporins, 
fluoroquinolones and macrolides in food producing animals. 
Table 2. Antimicrobial classes deemed critically important for human medicine which are currently 
licensed for use in food producing animals in the UK. Classes where there is particular concern over current 
use in food producing animals are marked with an asterisk. 
Class Farm animal veterinary examples 
Aminoglycosides Dihydrostreptamycin, Framycetin, Kanamycin, 
Neomycin, Streptomycin  
Cephalosporins* Third generation Ceftiofur, Cefoperazone 
Fourth generation Cefquinome 
Fluoroquinolones* Danofloxacin, Enrofloxacin, Marbofloxacin 
Macrolides* Gamithromycin, Tildipirosin, Tilmicosin, 
Tulathromycin, Tylosin 
Penicillins Ampicillin, Amoxycillin, Penicillin G, Penethamate 
hydroiodide 
 
However, co-selection for AMR means that simply reducing the use of these classes alone is insufficient to 
tackle the challenge of AMR, although it should slow resistance development to these classes. For example, 
use of tetracyclines may select for cephalosporin resistance in certain cases (Kanwar and others, 2014).  Thus, 
as total antimicrobial use on farm is the biggest driver of AMR, it is this that must be tackled. 
Even so, when selecting therapy on farm, first-line AMs, which may be defined as the narrowest spectrum 
products appropriate to the likely causal organisms in each, must always be selected in the first instance. 
This excludes critically important AMs.  
Developing and implementing a practice policy for responsible medicines use 
Governing principles 
In order to effectively develop and fully implement a practice policy for responsible medicines use, the 
following principles are important 
• SMART (Specific, Measurable, Achievable, Relevant and Time-bound) objectives – Local knowledge 
of the existing practice approach, established patterns of use and attitudes of VS and farmers is 
invaluable when it comes to developing a practice-specific AM policy.  It is important to consider 
what general principles of good practise would look like when applied to the specific practice context. 
This will enable any plan for change to be both prioritised and realistic, with a clear expectations of 
the timeframe in which objectives may be achieved. Establishment of these approaches will 
inevitably depend on and be relevant to the starting point, in terms of pre-existing attitudes and 
current prescribing practices. For example, one objective might be to include discussions on 
medicines use a part of HHM reviews, another might be to target reducing the use of 
fluoroquinolones. A third could include running a series of farmer meetings or producing some 
newsletter articles to raise awareness amongst the client base. Outcomes should be measurable (e.g. 
achieving a 20% reduction in the total mass of 3rd and 4th generation cephalosporins used), so 
progress can be demonstrated, recognised, rewarded and encouraged. Start small and build 
momentum.  The Anglo-Irish politician and philosopher Edmund Burke (1729-1797) once said 
“Nobody made a greater mistake than he who did nothing because he could only do a little!”  The 
objectives will inevitably change with progress, but clearly defining smaller objectives allows progress 
to be measured and success to be recognised and praised. 
 
• Strong leadership and cultural change – As with other aspects of clinical governance, strong and 
enthusiastic leadership can help to achieve change. In some practices this will involve significant 
cultural change. Directly challenging the established status quo and confronting the opinions and 
practices of influential, potentially senior members of staff may be required.  A wider adoption of 
EBVM goes hand-in-hand with this approach, because establishing cultural norms for practice 
becomes more about the science than about personalities and opinions based on anecdotes and 
seniority, unsubstantiated by clear evidence.   
 
• Practice-wide involvement – It is essential that all members of the practice team take ownership of 
responsible medicines use within the practice: they must understand and commit to both developing 
and supporting the implementation of any practice-wide policy, particularly with respect to critically 
important AMs(Figure 3). This cannot be a solo effort if it is to be sustainable. It is especially 
important for support and administrative staff – particularly those who are client facing or with 
responsibility for pharmacy management or dispensing – to take a central role. Practical solutions 
might involve a traffic light system to colour code pharmacy shelves or established prescribing lists 
for each farm.  If the whole practice team is involved in presenting a coherent and consistent 
message to the client base and the VSs routinely model the same diligent approach to responsible 
prescribing, then the impact will be greater. Training of staff at all levels is critical, in order to equip 
the whole team with the skills and resources necessary for change. 
 
 
 
Figure 3. Langford Farm Animal Practice: Protocol for the use of critically important antimicrobials.  
(The term protected antimicrobials here refers to third and fourth generation cephalosporins, fluoroquinolones and the longer acting 
macrolides). 
 
• Participatory and collaborative – The team at Langford Farm Animal Practice (LFAP), a clinical 
teaching practice of the University of Bristol, School of Veterinary Sciences, found that one of the 
key factors for success in achieving behavioural change towards more responsible use amongst 
farmers and VSs was adopting a collaborative approach.  Farmers were drawn in as partners in the 
process, and practice policy and behavioural change moved forwards together. A concerted 
programme of client education through intentional farmers’ meetings and targeted newsletter 
articles was important, but it was the intentional one-to-one, on-farm conversations as part of HHM 
that helped to make change sustainable.  The challenge of responsible medicines use needs to be 
one that farmers and VSs tackle together, though the leadership from this should come from 
veterinary practices.  
 
• EBVM-driven – Farm animal VS must have the skills and knowledge required for rational, responsible 
prescribing, be able to critically review medicines use on farm within the context of HHM and be 
skilled in motivating very necessary change in this area. In the absence of widely available, rapid, 
patient-side diagnostics, in the short-term, the majority of prescribing decisions will still be made on 
an empirical basis. Therapeutic best-practice, as far as can be established from the available 
evidence base, should be the starting point. Excellent online training resources to support VS in the 
application of EBVM to clinical practice are available through EBVM Learning 
(www.ebvmlearning.org), funded by RCVS Knowledge. Existing good-practice guidelines should be 
adopted, for example the BVA 7-Point Plan (Figure 4) and the Responsible Use of Medicines in 
Agriculture (RUMA) Alliance guidelines (RUMA, 2015). It is the intention of the Veterinary Medicines 
Directorate (VMD) that the UK Veterinary Antibiotic Resistance and Sales Surveillance (UK-VARSS) 
report should influence and inform prescribing habits and herd health management decisions on 
farm (VMD, 2013) 
 
 
Figure 4. BVA 7-Point Plan: Responsible use of antimicrobials in veterinary practice 
 
• Client education – Given that in farm animal practice the majority of treatments are administered by 
animal keepers, rather than VSs, it is critical that farm clients are actively involved in the process of 
change.  The VS and farmers must embark on a journey of change together where the need to 
challenge current practices can be established first, before a shared way forwards is agreed.  Client 
education is key, taking the form of farmers’ meetings or newsletter articles. It is important to start 
where your clients are. Participatory approaches often work best with farmers having an opportunity 
to learn from one another, with or without farm level benchmarking as a starting point for discussion, 
however, the importance of the individual, one to one, VS to farmer dialogue should not be under-
estimated. Using the theory of planned behaviour, a recent UK study established that the strongest 
driver to reduce AM use was the perception that their social networks and advisers would approve 
of this (Jones and others, 2015).  Veterinary Surgeons have the potential to be highly influential in 
affecting behavioural change and should be equipped to do this, through appropriate communication 
skills training (e.g. motivational interviewing).  The critical step is that the approach needs to be 
participatory and the farmers need to ‘buy in’ to the process.  Simply telling clients what you think 
they should do, will not bring about lasting behavioural change! 
 
• Sustainability – Developing a culture of practice that lasts is essential; to be sustainable, change 
must extend beyond the influence of a small number of key individuals who may have been 
important in the conception and introduction of new approaches, but cannot carry them forward in 
isolation or indefinitely.  Establishing agreed written protocols can help, but this needs to be more 
than a paper exercise. Habituating staff to an ongoing process of training, discussion and re-training 
within this area is key. Internal CPD training for inexperienced staff and, if appropriate, re-training 
of experienced members of the team will help to ensure that training can be sustained. Practice 
policies on antimicrobial use should form part of the induction process of any new member of staff, 
regardless of their role within the practice.  Responsible medicine use must become the cultural 
norm within the practice and be embed in, and underpin, every aspect of clinical practice. 
 
• Clinical governance and auditing medicines use – In order for antimicrobial use to be considered 
truly responsible, it must be measured, monitored and reviewed by farm animal VSs, as should all 
other aspects of HHM.  Systematic farm- and practice-level medicines auditing is a useful way in 
which this can be achieved. Audits such as these identify key opportunities for improvements, allow 
benchmarking of progress, and have played an important role in changing patterns of antimicrobial 
use within the LFAP (Tisdall and others, 2015). 
 
Case study: Langford Farm Animal Practice 
The LFAP has a long history and developed culture of proactively engaging with farm clients to encourage 
responsible AM use.  Reducing total AM use while driving more responsible use on farms – optimising AM 
use – is likely to have the biggest impact in slowing AMR development (Department of Health, 2013).  
Approach 
A collaborative approach, working alongside farmers to improve HHM and informed by systematic farm-
level medicines auditing coupled with farmer training and intentional changes in prescribing policy has 
proved highly successful in achieving this change (Figure 5). Farmers’ meetings and regular newsletter 
articles were used to raise awareness, provide training on compliance and responsible antimicrobial use and 
to encourage engagement by farmers.   
 Figure 5. Integration of medicines audits with HHM and clinical governance 
 
Consideration of both animal health and economic implications of current medicines use - including the 
balance between preventive interventions (e.g. HHM, vaccination and non-antibiotic dry cow therapy) and 
reactive treatments (e.g. systemic antibiotics, lactating cow therapy and non-steroidal anti-inflammatory 
drugs) - allowed targeted recommendations to both reduce disease and improve profitability. Areas of good 
practice and responsible medicines use were identified, emphasised and encouraged, and poor compliance 
highlighted.   
Table 3. illustrates the major practice level changes in AM prescribing policy. 
Table 3. Major practice level changes in AM prescribing policy 
Area of use Changes in prescribing policy 
Intra-mammary use Fourth-generation cephalosporins phased out in favour of penicillin and 
aminoglycoside combinations 
Systemic use  Fluoroquinolone use halted. 
Third- / fourth- generation cephalosporins were replaced with first-
generation cephalosporins or aminopenicillins.  
Calf pneumonia Longer-acting macrolides were replaced with oxytetracycline or 
florfenicol and a greater emphasis placed on non-antimicrobial therapies 
(e.g. NSAIDs). 
 
An annual retrospective analysis of medicines use data at practice level from 2010 onwards was carried out 
to assess the impact of this approach. Multiple measures were used to benchmark medicines use. In 
particular, animal daily dose (mg/kg/day) and number of doses or courses per animal year at risk have been 
used at farm level, when herd size and profile could be accurately established. Economic measures (e.g. 
pence per litre on medicines spend) were also included. At practice level, due to the broad range of species 
catered for, total milligrams used per year was found to be an appropriate metric to monitor total use.   
 
Results 
Between 2010 and 2015, a 100% reduction in intramammary use and a 91% reduction in the systemic use of 
certain critically important antimicrobials (CIAs) has been achieved, namely third- and fourth-generation 
cephalosporins, fluoroquinolones and long-acting macrolides (Figure 6). Total antimicrobial use was reduced 
by 7% between 2014 and 2015, having remained relatively static for the previous five years against a 10% 
increase in dairy cattle numbers (Figure 7). No fluoroquinolones have been used since 2009.  
 
Figure 6 – Use of antimicrobials critically important for human health 
 Figure 7 – Total antimicrobial use 
Although total antimicrobial use at practice level in the LFAP has remained relatively constant. In real terms, 
this actually represents a reduction in the number of courses of antimicrobials prescribed per animal, given 
factors such as 1) the 10% increase in dairy cattle numbers, 2) the training emphasis placed on accurate 
dosing and course completion, and 3) the relatively higher dose rates of alternative products (e.g. the dose 
rate of amoxicillin is 7 mg/kg compared to 1 mg/kg for ceftiofur).  
There was no evidence of declining herd health or cure rates (whether real or farmer-perceived) with a move 
away from the use of CIAs. Improved farm management and preventive strategies have continued to lead 
to reduced levels of disease. Clinical mastitis is one such example, demonstrating a 32% reduction in the use 
of lactating cow therapy (Figure 7). Dairy farm-level disease incidence data also supports this conclusion 
(data currently under analysis). 
  
Figure 7. Use of lactating cow therapy for the treatment of clinical mastitis 
Concern over farmer willingness to participate in change, although widely discussed, was proved to be 
unfounded. It is likely that the collaborative approach employed by LFAP practitioners and clients 
contributed to success, building upon the existing, well-developed relationship of trust between farmers and 
practice VSs. Farm clients have been consistently positive about tackling the issues of responsible medicines 
use and AMR in partnership with the practice. This is consistent with the findings of Jones and others (2015).    
Challenges to systematic medicines auditing 
Establishing correct benchmarks 
Careful consideration should be given when considering appropriate benchmarking measures.   
The first challenge is defining the most appropriate measures for medicines use at farm level, bearing in 
mind that context and the user (e.g. VS, farmer or central authority) will influence what are the most 
appropriate measures.  Defining the population at risk is challenging. For this reason, total kgs of 
antimicrobials may be a more appropriate measures at practice level, particularly when a diverse range of 
species and types of animals are cared for. 
Informal feedback suggests farmers have found measures which express antimicrobial use in terms of doses, 
courses or economics most useful. 
Making the correct assumptions 
When using information about practice medicines sales as a proxy for on-farm medicine use, assumptions 
about data quality, standard treatment protocols and background population are unavoidable. Cross-
checking these assumptions against on-farm practise is key, but can also be a useful and informative part of 
the HHM review and arguably something that should be happening anyway to ensure responsible use.  There 
will be some inaccuracies in medicines sales data extracted from practice recording systems; the 
completeness and accessibility of these, however, are likely to exceed that of on-farm treatment records, 
making them a valuable data resource. 
Conclusions 
Changes to prescribing practices as described here may have reduced the selection pressure for AMR. On 
dairy farms, recent use of third- and fourth-generation cephalosporins is strongly associated with an 
increased likelihood of the presence of extended-spectrum beta-lactamase E. coli (specifically CTX-M), while 
use of first and second generation cephalosporins is not similarly associated (Snow and others, 2012).  
For veterinarians interested in responding to the threat of AMR, this work shows it is possible to achieve 
marked reductions in the use of critically important antimicrobials in food-producing animals alongside 
reductions in total use, whilst keeping farmers on board and continuing to improve animal health and 
welfare, and without the need for legislation. The continued use of CIAs as first line treatments cannot be 
justified and should be phased out as a matter of priority.  The need for change is clear and our experience 
is that farmers are keen to play their part. We do not need to wait for legislation to force change upon the 
livestock sector, these very necessary changes should be led by the veterinary profession now in 
collaboration with livestock producers.   
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